Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

IF 4.5 2区医学 Q2 IMMUNOLOGY

Journal of Microbiology Immunology and Infection Pub Date : 2024-02-01 DOI:10.1016/j.jmii.2023.09.004

Tal Brosh-Nissimov , Nir Ma'aravi , Daniel Leshin-Carmel , Yonatan Edel , Sharon Ben Barouch , Yafit Segman , Amos Cahan , Erez Barenboim

{"title":"Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab","authors":"Tal Brosh-Nissimov , Nir Ma'aravi , Daniel Leshin-Carmel , Yonatan Edel , Sharon Ben Barouch , Yafit Segman , Amos Cahan , Erez Barenboim","doi":"10.1016/j.jmii.2023.09.004","DOIUrl":null,"url":null,"abstract":"<div><p>We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.</p></div>","PeriodicalId":56117,"journal":{"name":"Journal of Microbiology Immunology and Infection","volume":"57 1","pages":"Pages 189-194"},"PeriodicalIF":4.5000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1684118223001706/pdfft?md5=49414879769acb8629ee0e171017edc8&pid=1-s2.0-S1684118223001706-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Microbiology Immunology and Infection","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1684118223001706","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.

查看原文本刊更多论文

联合治疗免疫功能低下患者的持续性新冠肺炎，使用瑞德西韦、尼马替韦/利托那韦和替昔加韦单抗/西加韦单抗。

我们对患有持续性新冠肺炎的严重免疫功能低下患者的治疗结果进行了回顾性研究。该研究分析了14名接受替加韦单抗/西加韦单抗联合抗病毒药物治疗的患者的数据。根据症状改善、聚合酶链式反应周期阈值和C反应蛋白水平评估疗效。11名患者获得了完全的临床和病毒学解决，3名患者出现了部分反应。该研究表明，无反应与替加韦单抗/西加韦单抗中和之间存在潜在联系。研究结果强调，需要量身定制治疗方法，进一步研究管理持续性新冠肺炎的最佳策略，以及开发抗病毒药物和变体特异性单克隆抗体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Microbiology Immunology and Infection IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

15.90

自引率

5.40%

发文量

159

审稿时长

67 days

期刊介绍： Journal of Microbiology Immunology and Infection is an open access journal, committed to disseminating information on the latest trends and advances in microbiology, immunology, infectious diseases and parasitology. Article types considered include perspectives, review articles, original articles, brief reports and correspondence. With the aim of promoting effective and accurate scientific information, an expert panel of referees constitutes the backbone of the peer-review process in evaluating the quality and content of manuscripts submitted for publication.